Cell viability results from KPC BRCA2-proficient murine pancreatic tumor cells and BRCA2-deficient KPB tumor cells confirmed higher cytotoxicity of Niraparib in pancreatic cancer regardless of BRCA status (Figure S1). Here, BRCA2 is linked to familial pancreatic carcinoma.